Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Investigate the Safety, Tolerability, and Immunogenicity of Revaccinating Pregnant Participants During Subsequent Pregnancies and Persistence of Immunity of a Single Dose of a Bivalent Respiratory Syncytial Virus (RSV) Vaccine.

NCT06866405 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06866405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06866405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Investigate the Safety, Tolerability, and Immunogenicity of Revaccinating Pregnant Participants During Subsequent Pregnancies and Persistence of Immunity of a Single Dose of a Bivalent Respiratory Syncytial Virus (RSV) Vaccine.
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Recruiting
Start date
April 16, 2025
Completion date
February 24, 2028
Enrollment
550 (estimated)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

rsv infection